Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Abstract
Preclinical data provide evidence for synergism between HER2-targeted peptide vaccines and trastuzumab. The efficacy of this combination was evaluated in patients with HER2 low-expressing breast cancer in the adjuvant setting.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2741
Entities
People
- Anne V. Philips
- Annelies T. Hickerson
- Diane Hale
- Elizabeth A. Mittendorf
- George E. Peoples
- Gheath Alatrash
- Guy T. Clifton
- Jarrod P. Holmes
- Jason J. Lukas
- Jennifer K. Litton
- Na Qiao
- Rashmi K Murthy
- Timothy J Vreeland
Organizations
- Nancy Owens Memorial Foundation
- National Cancer Institute
- San Antonio Military Medical Center
- The University of Texas MD Anderson Cancer Center
- University of Texas at Austin
- University of Washington